HTGF’s Ayoxxa Biosystems closes €9m series-B

Existing investors KFW, NRW Bank, Wellington Partners and private backers, as well as new investors b-to-v Partners, Creathor Venture and HR Ventures, committed to the series-B. Additionally, several individuals from the US and Europe, including Ayoxxa employees and two of Qiagen's founders, took part in the round.

Ayoxxa stated that an expanded biotechnology and pharmaceutical network would facilitate commercialisation of its technology in the near future and help scale the production of Ayoxxa's proprietary biochips.

Previous funding
HTGF, Wellington, NRW and other private investors participated in Ayoxxa's €2.6m series-A financing round in September 2012. The round was led by Wellington.

Company
Founded in 2010, Ayoxxa is an international biotech that has developed a proprietary technology platform for multiplex protein analysis. It aims to commercialise its in-situ encoded bead array (IEBA) technology to allow users to combine screening and multiplexed assay formats. Based in Cologne, Germany, the firm has an additional office in Singapore.

People
Andreas Schmidt is the CEO of Ayoxxa. Wellington general partner Regina Hodits and HTGF investment manager Matthias Dill worked on the original deal.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• DACH
• Healthcare
• Early-stage
• Germany
• High-Tech Gründerfonds
• Wellington Partners